Phase 2 Zika vaccine trial begins in U.S., Central and South America
by Press Release from Outbreak News Today on (#2HR44)
Vaccinations have begun in a multi-site Phase 2/2b clinical trial testing an experimental DNA vaccine designed to protect against disease caused by Zika infection. The vaccine was developed by government scientists at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). NIAID is leading the trial, which ["]
The post Phase 2 Zika vaccine trial begins in U.S., Central and South America appeared first on Outbreak News Today.